Today: 30 June 2026
Sembcorp Industries stock dips as Sprng Energy bid talk resurfaces; Alinta vote nears
10 January 2026
1 min read

Sembcorp Industries stock dips as Sprng Energy bid talk resurfaces; Alinta vote nears

Singapore, Jan 10, 2026, 15:29 (SGT) — Market closed

  • Sembcorp Industries shares ended Friday down 0.7% at S$5.99
  • Media reports linked Sembcorp to a bidding race for Shell-owned Indian renewables platform Sprng Energy
  • Sembcorp’s planned Alinta Energy purchase is a cash deal backed by a fully committed A$6.5 billion bridge facility, an SGX filing showed

Sembcorp Industries Ltd shares (U96.SI) closed at S$5.99 on Friday, down 0.66%, after a media report linked the Singapore-listed utility to a bidding race for Shell’s Indian renewable energy platform Sprng Energy. The stock has now slipped for two straight sessions.

The timing matters. Sembcorp is heading into a shareholder vote window for its planned purchase of Australia’s Alinta Energy — a deal that would be paid in cash and would widen the group’s exposure to regulated power and fuel markets outside Singapore.

The Economic Times reported that Sembcorp, U.S. private equity firm KKR and India’s National Investment and Infrastructure Fund had submitted non-binding offers for Sprng, with bids only turning binding after due diligence. Macquarie was also said to have made an offer, the report added.

On Friday, Sembcorp traded between S$5.96 and S$6.03, with about 4.52 million shares changing hands, according to daily price data. It fell about 1% a day earlier.

Sembcorp agreed in December to buy Alinta for an enterprise value of A$6.5 billion ($4.32 billion), a move that would give it control of one of Australia’s major integrated energy retailers and generators. Reuters reported Alinta serves about 1.1 million customers and runs 3.4 gigawatts of capacity across gas, coal, wind and solar.

A company presentation said Sembcorp expects to dispatch its shareholder circular and notice of an EGM — an extraordinary general meeting — in mid-January, with the vote pencilled in for end-January. It also flagged completion in the first half of 2026, subject to shareholder and regulatory approvals, including reviews by Australia’s Foreign Investment Review Board and the competition regulator.

With the market shut for the weekend, traders will likely keep one eye on the S$6 handle. Friday’s low at S$5.96 sits close by; the day’s high at S$6.03 is the first level bulls will want back.

But a lot could still go differently. Any Sprng deal — if it progresses beyond reports — would sharpen questions on price, leverage and management bandwidth just as Sembcorp works through approvals for Alinta, and delays would push out the timetable and keep the stock headline-driven.

The next hard marker is Sembcorp’s full-year earnings, due on Feb. 23, according to TradingView’s calendar, for clues on funding plans and how fast the group wants to keep buying.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
Lululemon stock drops nearly 4% as tariff ruling stays unresolved — what to watch next
Previous Story

Lululemon stock drops nearly 4% as tariff ruling stays unresolved — what to watch next

Boeing stock climbs as FAA proposes new 737 inspections and investors eye delivery data
Next Story

Boeing stock climbs as FAA proposes new 737 inspections and investors eye delivery data

Go toTop